MK-0633;4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one;4-(4-fluorophenyl)-7-[[[5-[(2S)-1,1,1-trifluoro-2-hydroxybutan-2-yl]-1,3,4-oxadiazol-2-yl]amino]methyl]chromen-2-one;Setileuton;2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-;Setileuton, 10 mM in DMSO
MK-0633 (Setileuton) is a 5-lipoxygenase inhibitor that suppresses the oxidation of arachidonic acid by human recombinant 5-lipoxygenase and inhibits calcium ionophore-stimulated LTB4 production in human whole blood, with IC50 values of 3.9 nM and 52 nM, respectively.